To evaluate the impact of FASN-driven de novo FA synthesis on tumor cell responses to T cells, we performed impedance-based real-time monitoring of the cytolytic response to cell-based immunotherapy in co-isogenic cell lines that were either wild-type or deficient in the FASN gene (Fig. S1). The gene discussed is FASN; the disease is neoplasm.